[1,2-Bis(2-hydroxyphenyl)ethylenediamine]dichloroplatinum(II), a new compound for the therapy of ovarian cancer. II. Synthesis and preliminary testing of the enantiomeric complexes

J Cancer Res Clin Oncol. 1992;118(3):201-8. doi: 10.1007/BF01410135.

Abstract

The enantiomeric [1,2-bis(2-hydroxyphenyl)-ethylenediamine]dichloroplatinum(II) complexes were synthesized and their configuration assessed. A preliminary test in the cisplatin-resistant human NIH:OVCAR-3 ovarian cancer cell line, which was previously characterized by its sensitivity against several therapeutically used drugs, showed that both enantiomers produce cytocidal effects in a concentration of 2.5 microM. A difference between the enantiomers became evident from the faster onset of cytocidal activity of the S,S-configurated compound.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenocarcinoma / drug therapy
  • Adenocarcinoma / genetics
  • Adenocarcinoma / pathology*
  • Antineoplastic Agents / chemical synthesis*
  • Antineoplastic Agents / chemistry
  • Antineoplastic Agents / pharmacology
  • Chromosome Aberrations
  • Female
  • Humans
  • Molecular Conformation
  • Organoplatinum Compounds / chemical synthesis*
  • Organoplatinum Compounds / pharmacology
  • Ovarian Neoplasms / drug therapy
  • Ovarian Neoplasms / genetics
  • Ovarian Neoplasms / pathology*
  • Stereoisomerism
  • Tumor Cells, Cultured / drug effects

Substances

  • Antineoplastic Agents
  • Organoplatinum Compounds
  • (1,2-bis(2-hydroxyphenyl)ethylenediamine)dichloroplatinum (II)